keyword
https://read.qxmd.com/read/38510285/comparing-anticoagulation-strategies-for-venous-thromboembolism-associated-with-active-cancer-a-systematic-review-and-meta-analysis
#1
JOURNAL ARTICLE
Tomohiro Fujisaki, Daisuke Sueta, Eiichiro Yamamoto, Conor Buckley, Guilherme Sacchi de Camargo Correia, Julia Aronson, Paulino Tallón de Lara, Koichiro Fujisue, Hiroki Usuku, Kenichi Matsushita, Roxana Mehran, George D Dangas, Kenichi Tsujita
BACKGROUND: Current guidelines recommend several direct oral anticoagulant agents (DOACs) equally for managing cancer-associated venous thromboembolism (VTE). OBJECTIVES: The aim of this study was to assess the efficacy and safety of DOACs in patients with active cancer. METHODS: Literature searches were conducted in PubMed, Embase, and Cochrane Central in November 2022. Randomized controlled trials investigating anticoagulation strategies (vitamin K antagonists, parenteral anticoagulation [eg, low-molecular weight heparin], and DOACs) for VTE in patients with active cancer were identified for network meta-analysis...
February 2024: JACC CardioOncology
https://read.qxmd.com/read/38494772/-mid-term-analysis-of-prospective-cohort-study-of-rivaroxaban-in-preventing-crt-in-breast-cancer
#2
JOURNAL ARTICLE
D Sang, S M Fan, S Y Li, J T Zhang, H M Wang, X H Zhao, L J Zheng, P Liang, G B Xi, L M Zhao, Y R Zhang, P Yuan
Objective: To explore the efficacy and safety of Rivaroxaban in preventing catheter related thrombosis (CRT) in patients with breast cancer who are undergoing central venous catheter chemotherapy, and provide basis for making standardized prevention and treatment strategies. Methods: In this research, a prospective cohort study was adopted, and breast cancer patients who received central venous catheter chemotherapy in Sanhuan Cancer Hospital during September 2020 to March 2022 were selected as a treatment group to take the rivaroxaban anticoagulation therapy with 10 mg...
March 23, 2024: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/38462535/home-treatment-for-active-cancer-patients-with-low-risk-pulmonary-embolism%C3%A3-a-predetermined-companion-report-from-the-onco-pe-trial
#3
JOURNAL ARTICLE
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Wataru Shioyama, Tatsuhiro Shibata, Yuji Nishimoto, Yoshito Ogihara, Kosuke Doi, Maki Oi, Taro Shiga, Daisuke Sueta, Kitae Kim, Yasuhiro Tanabe, Norimichi Koitabashi, Takuma Takada, Satoshi Ikeda, Hitoshi Nakagawa, Takayuki Mitsuhashi, Masaaki Shoji, Jiro Sakamoto, Shinji Hisatake, Yutaka Ogino, Masashi Fujita, Naohiko Nakanishi, Tomohiro Dohke, Seiichi Hiramori, Ryuzo Nawada, Kazuhisa Kaneda, Kazunori Mushiake, Hiromi Yamamoto, Kazushige Kadota, Koh Ono, Takeshi Kimura
BACKGROUND: Patients with appropriately selected low-risk pulmonary embolism (PE) can be treated at home, although it has been controversial whether applies to patients with cancer, who are considered not to be at low risk.Methods and Results: The current predetermined companion report from the ONCO PE trial evaluated the 3-month clinical outcomes of patients with home treatment and those with in-hospital treatment. The ONCO PE trial was a multicenter, randomized clinical trial among 32 institutions in Japan investigating the optimal duration of rivaroxaban treatment in cancer-associated PE patients with a score of 1 using the simplified version of the Pulmonary Embolism Severity Index (sPESI)...
March 8, 2024: Circulation Journal: Official Journal of the Japanese Circulation Society
https://read.qxmd.com/read/38451960/safety-profile-of-rivaroxaban-in-first-time-users-treated-for-venous-thromboembolism-in-four-european-countries
#4
JOURNAL ARTICLE
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez
BACKGROUND: The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice. METHODS: Cohorts were created using electronic healthcare databases from the UK, the Netherlands, Germany and Sweden. Patients with a first prescription of rivaroxaban or vitamin K antagonist during the period from December 2011 (in the UK, January 2012) to December 2017 (in Germany, December 2016) for venous thromboembolism indication, with no record of atrial fibrillation or recent cancer history, were observed until the occurrence of each safety outcome (hospitalization for intracranial, gastrointestinal, urogenital or other bleeding), death or study end (December 2018; in Germany, December 2017)...
2024: PloS One
https://read.qxmd.com/read/38449356/real-world-experience-of-direct-oral-anticoagulant-use-in-a-single-pediatric-center
#5
JOURNAL ARTICLE
Gianna G Valenti, Cynthia Sabo, Michelle Hyde, Madhvi Rajpurkar
BACKGROUND: Pediatric venous thromboembolism has increased by 130%-200%, specifically in hospitalized children, and direct oral anticoagulants (DOACs) offer several therapeutic advantages. METHODS: This study aims to evaluate the real-world epidemiological and outcome data from a retrospective review of pediatric patients treated with DOACs from January 1, 2013 to December 31, 2022. In this single-center, IRB-approved study, 65 patients were identified and analyzed using SPSS statistical software, and a descriptive statistical analysis was conducted...
March 6, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38440888/patient-characteristics-associated-with-using-transcatheter-left-atrial-appendage-occlusion-versus-oral-anticoagulants-for-atrial-fibrillation
#6
JOURNAL ARTICLE
Kueiyu Joshua Lin, Daniel E Singer, Jerry Avorn, E Kevin Heist, Sushama Kattinakere Sreedhara, Priyanka Anand, Yichi Zhang, Theodore N Tsacogianis, Sebastian Schneeweiss
BACKGROUND: Transcatheter left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulants (OACs) for stroke prevention in patients with atrial fibrillation, but the predictors of LAAO use in routine care are unclear. We aimed to assess the utilization trends of LAAO and compare the change in characteristics of LAAO users versus OACs since its marketing. METHODS: Using the US Medicare claims database (March 15, 2015, to December 31, 2020), we identified patients with atrial fibrillation, ≥65 years, and CHA2 DS2 -VASc score ≥2 (men) or ≥3 (women), with either first implantation of an LAAO device or initiation of OACs, including apixaban, dabigatran, rivaroxaban, edoxaban, or warfarin...
March 5, 2024: Circulation. Cardiovascular Quality and Outcomes
https://read.qxmd.com/read/38412982/-venous-thromboembolism-was-is-new-in-the-revised-awmf-guideline
#7
JOURNAL ARTICLE
Birgit Linnemann, Katja Sibylle Mühlberg, Robert Klamroth
For the diagnosis of a lower-extremity deep vein thrombosis (LEDVT), venous duplex ultrasound is the method of first choice. If a qualified ultrasonography is not timely available, D-dimer testing, and limited ultrasound protocols (point-of-care ultrasound, POCUS) can contribute to therapeutic decision-making when clinical probability is low. A DOAC-based treatment regimen is preferable to a vitamin K antagonist for both acute therapy and secondary prophylaxis of venous thromboembolism (VTE). Treatment with DOACs is unproblematic up to a body weight (BW) of 120 kg or a body mass index (BMI) of 40 kg/m²...
March 2024: Deutsche Medizinische Wochenschrift
https://read.qxmd.com/read/38348537/cancer-associated-non-bacterial-thrombotic-endocarditis-clinical-series-from-a-single-institution
#8
JOURNAL ARTICLE
Patryk Patrzalek, Waldemar E Wysokinski, Reto D Kurmann, Damon Houghton, David Hodge, Wiktoria Kuczmik, Kyle W Klarich, Ewa M Wysokinska
Premortem clinical presentation of cancer-associated non-bacterial thrombotic endocarditis (Ca-NBTE), therapy, and the clinal course is limited to case reports and small clinical series. An electronic search of Mayo Clinic records (03/31/2002-06/30/2022) with a subsequent manual review was performed to identify adult patients with echocardiographically detected NBTE and active malignancy, excluding those with infectious endocarditis or lupus anticoagulant/antiphospholipid antibodies. In this retrospective cohort study, we analyzed 115 Ca-NBTE patients (mean age 63...
April 2024: American Journal of Hematology
https://read.qxmd.com/read/38325530/trends-in-deep-vein-thrombosis-prophylaxis-after-total-knee-arthroplasty-2016-to-2021
#9
JOURNAL ARTICLE
Jeremy A Dubin, Sandeep S Bains, Daniel Hameed, Ethan A Remily, Mallory C Moore, Michael A Mont, James Nace, Ronald E Delanois
INTRODUCTION: In 2011, the American Academy of Orthopaedic Surgeons released a consensus recommending venous thromboembolism (VTE) prophylaxis after total knee arthroplasty (TKA). The purpose of our study was to examine: (1) incidences of postoperative complications, including pulmonary embolism (PE), deep vein thrombosis (DVT), and transfusion rates; (2) trends from 2016 to 2021 in VTE prophylaxis; as well as (3) independent risk factors for 90-days total complications following TKA between aspirin, enoxaparin, rivaroxaban, and warfarin...
February 5, 2024: Journal of Arthroplasty
https://read.qxmd.com/read/38303337/-hemorrhagic-colon-cancer-with-left-atrial-thrombus-formation-after-anticoagulant-therapy-discontinuation-a-case-report
#10
JOURNAL ARTICLE
Shingo Seo, Aki Kuwada, Tatsunori Hashimoto, Yuta Kuhara, Ai Amioka, Naoki Murao, Akira Nakashima, Ryutaro Sakabe, Hiroshi Hotei, Ko Tahara, Sayako Nagata, Yoshihiro Dohi
The patient was a 72-year-old female. She had been taking rivaroxaban for chronic atrial fibrillation; however, she stopped taking it due to anemia and was hospitalized urgently. A contrast-enhanced computed tomography(CT)scan showed a 30 mm mass in the ascending colon, and a colonoscopy revealed ascending colon cancer(cT3, cN0, cM0, cStage Ⅱa). The tumor was hemorrhagic and was thought to have caused the anemia. On day 6 of hospitalization, another contrast- enhanced CT scan showed a poorly contrast-enhanced area in the left atrium, and transesophageal echocardiography revealed 2 left atrial thrombi(27 mm and 17 mm)...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38301711/comparison-of-clinical-outcomes-in-patients-with-active-cancer-receiving-rivaroxaban-or-low-molecular-weight-heparin-the-oscar-uk-study
#11
Alexander Cohen, Christopher Wallenhorst, Marcela Rivera, Cihan Ay, Bernhard Schaefer, Khaled Abdelgawwad, George Psaroudakis, Gunnar Brobert, Anders Ekbom, Agnes Y Y Lee, Alok A Khorana, Cecilia Becattini, Marc Carrier, Craig I Coleman, Carlos Martinez
BACKGROUND: In most patients with cancer-associated venous thromboembolism (CAT), essentially those not at high-risk of bleeding, guidelines recommend treatment with direct oral anticoagulants as an alternative to low molecular weight heparins (LMWHs). Population-based studies comparing these therapies are scarce. OBJECTIVES: To compare the risk of venous thromboembolism (VTE) recurrences, significant bleeding and all-cause mortality in patients with CAT, receiving rivaroxaban or LMWHs...
February 1, 2024: Thrombosis and Haemostasis
https://read.qxmd.com/read/38286976/clinical-and-molecular-determinants-of-bleeding-related-adverse-outcomes-in-high-grade-glioma
#12
JOURNAL ARTICLE
Pushan Dasgupta, Justin F Rousseau
PURPOSE: Cancer is an independent risk factor for the development of venous thromboembolism (VTE). However, patients with high-grade glioma (HGG) including glioblastoma (GBM) are at a particularly high risk of VTE with an incidence up to 20-30% per year. Patients are often placed on anticoagulation if they are found to have VTE. However, patients with primary brain tumors such as HGG are at increased risk for intracerebral hemorrhage (ICH) even without the administration of anticoagulation...
February 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38088911/patterns-of-anticoagulation-use-and-all-cause-of-mortality-in-cancer-patients-with-atrial-fibrillation
#13
JOURNAL ARTICLE
Xu Han, Xiaolei Yang, Tesfaldet H Hidru, Chengfang Wang, Yunlong Xia
BACKGROUND: There is uncertainty regarding the clinical benefit of anticoagulant (AC) treatment in patients with cancer with atrial fibrillation (AF). We aimed to evaluate the distribution and patterns of AC use and its impact on all-cause mortality in cancer patients with AF. METHODS: A total of 1,653 patients with cancer diagnosed with AF were included in this retrospective cohort analysis. Multivariable logistic regression was applied to identify the clinical predictors of anticoagulant prescription...
December 13, 2023: Cancer Epidemiology, Biomarkers & Prevention
https://read.qxmd.com/read/38084675/periprostatic-adipose-tissue-thromboinflammation-triggers-prostatic-neoplasia-in-early-metabolic-impairment-interruption-by-rivaroxaban
#14
JOURNAL ARTICLE
Ibrahim AlZaim, Nefertiti El-Nikhely, Aya Al-Saidi, Nahed Mougharbil, Nadine Darwiche, Wassim Abou-Kheir, Ahmed F El-Yazbi
AIMS: Prostate cancer is among the highest incidence malignancies in men with a prevalence rate increasing in parallel to the rising global trends in metabolic disorders. Whereas a sizeable body of evidence links metabolic impairment to negative prognosis of prostate cancer, the molecular mechanism underlying this connection has not been thoroughly examined. Our previous work showed that localized adipose tissue inflammation occurring in select adipose depots in early metabolic derangement instigated significant molecular, structural, and functional alterations in neighboring tissues underlying the complications observed at this stage...
December 1, 2023: Life Sciences
https://read.qxmd.com/read/38039346/low-dose-rivaroxaban-as-extended-prophylaxis-reduces-postdischarge-venous-thromboembolism-in-patients-with-malignancy-and-ibd
#15
JOURNAL ARTICLE
James W Ogilvie, Mariam T Khan, Emiko Hayakawa, Jessica Parker, Martin A Luchtefeld
BACKGROUND: Despite guidelines suggesting the use of extended prophylaxis for prevention of venous thromboembolism in patients with colorectal cancer and perhaps IBD, routine use is low and scant data exist regarding oral forms of therapy. OBJECTIVE: The purpose was to compare the incidence of postdischarge venous thromboembolism in patients given extended prophylaxis with low-dose rivaroxaban. DESIGN: We used propensity matching to compare pre- and postintervention analyses from a 2-year period before instituting extended prophylaxis...
March 1, 2024: Diseases of the Colon and Rectum
https://read.qxmd.com/read/37974596/direct-oral-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-obesity
#16
JOURNAL ARTICLE
Quinn Hattaway, Jessica A Starr, Nathan A Pinner
Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a decreased risk of bleeding when compared to warfarin for the treatment of venous thromboembolism (VTE). In patients with obesity, there are limited data regarding the safety and efficacy of DOACs. Despite concerns for both under- and over-dosing patients with extremes of body weight, there are no dose adjustment recommendations in the package inserts for any of the DOACs. Objective: To evaluate the safety and efficacy of DOACs versus warfarin for the treatment of VTE in patients with obesity...
December 2023: Journal of Pharmacy Technology: JPT: Official Publication of the Association of Pharmacy Technicians
https://read.qxmd.com/read/37914457/treatment-of-cancer-associated-venous-thromboembolism-a-focus-on-special-populations
#17
REVIEW
Alexandra Yannoutsos, Carlotta Cacciatore, Simon Jaouen, Dominique Farge, Corinne Frere
Current evidence-based clinical practice guidelines recommend the use of both low-molecular-weight heparin (LMWH) and direct factor Xa inhibitors (apixapan, edoxaban and rivaroxaban) as first-line options for the treatment of venous thromboembolism (VTE) in patients with cancer. However, most of these guidelines refer to the general cancer patient population and provide limited guidance for specific subgroups of patients at particularly high risk of bleeding, such as those with gastrointestinal cancers, primary or metastatic brain tumors, thrombocytopenia, or renal impairment...
September 2023: Journal de Médecine Vasculaire
https://read.qxmd.com/read/37913911/incidence-of-venous-thromboembolism-recurrence-and-bleeding-after-isolated-superficial-vein-thrombosis-findings-from-the-venous-thrombosis-registry-in-%C3%A3-stfold-hospital
#18
JOURNAL ARTICLE
Camilla Tøvik Jørgensen, Sigrid Kufaas Brækkan, Eli Førsund, Heidi Hassel Pettersen, Eirik Tjønnfjord, Waleed Ghanima, Mazdak Tavoly
BACKGROUND: There are limited data on the long-term risk of venous thromboembolism (VTE) after high-risk isolated superficial vein thrombosis (iSVT) treated with anticoagulants. OBJECTIVES: To determine the short- and long-term risk of VTE and iSVT recurrence after cessation of anticoagulant treatment and to calculate 45-day cumulative bleeding incidence in patients with iSVT. METHODS: Between January 2014 and December 2021, 229 patients with high-risk iSVT (ie, thrombus length ≥5cm), without active cancer, with no history of VTE or iSVT, and who had received anticoagulant treatment for the iSVT were identified through the Venous Thrombosis Registry in Østfold Hospital (TROLL registry), Norway...
October 31, 2023: Journal of Thrombosis and Haemostasis: JTH
https://read.qxmd.com/read/37860116/-in-vivo-evaluation-of-the-pharmacokinetic-interactions-between-almonertinib-and-rivaroxaban-almonertinib-and-apixaban
#19
JOURNAL ARTICLE
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations. Rivaroxaban and apixaban are a selective, direct factor Xa inhibitor used to treat venous thromboembolism (VTE), which is a frequent complication of NSCLC. Rivaroxaban and apixaban are substrates of CYP3A4, P-gp and BCRP, whereas almonertinib is an inhibitor of P-gp and BCRP. Rivaroxaban or apixaban are often prescribed together with almonertinib in NSCLC patients, but clear information on pharmacokinetic drug interaction is lacking...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37835070/low-dose-rivaroxaban-to-prevent-recurrences-of-venous-thromboembolism-in-cancer-a-real-life-experience-with-a-focus-on-female-patients
#20
JOURNAL ARTICLE
Paolo Santini, Carolina Mosoni, Alessandro D'Errico, Enrica Porceddu, Andrea Lupascu, Emanuele Valeriani, Paolo Tondi, Roberto Pola, Angelo Porfidia
BACKGROUND: The way in which to prevent recurrent venous thromboembolism (VTE) is an unmet clinical need in cancer patients. International guidelines only provide conditional recommendations and do not specify which anticoagulant and dose should be used. In the last 2 years, we have been using low-dose rivaroxaban to prevent VTE recurrences in cancer patients. The results of this real-life experience are presented in this study. METHODS: All patients had cancer and had previously completed a cycle of at least six months of full-dose anticoagulation for the treatment of a VTE index event, before receiving a prescription of low-dose rivaroxaban (10 mg once daily) for secondary prevention of VTE...
October 9, 2023: Journal of Clinical Medicine
keyword
keyword
120641
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.